利奈唑胺对临床分离阳性球菌的体外敏感性分析

中国临床药理学与治疗学 ›› 2008, Vol. 13 ›› Issue (9): 1048-1052.

利奈唑胺对临床分离阳性球菌的体外敏感性分析

肖秀美, 刘振英, 张晓伟, 张捷

北京大学第三医院检验科, 北京100191

收稿日期:2008-04-14 修回日期:2008-09-15 出版日期:2008-09-26 发布日期:2020-10-13
通讯作者: 张捷, 女, 教授, 博士生导师, 研究方向:临床生化。Tel:010-82266699 E-mail:bjmuzhangjie@tom.com

Sensitivity analyses of linezolid against clinical gram-positive cocci isolates in vitro

XIAO Xiu-mei, LIU Zheng-ying, ZHANG Xiao-wei, ZHANG Jie

Department of Laboratory Medicine, Third Hospital of Peking University, Beijing 100191, China

Received:2008-04-14 Revised:2008-09-15 Online:2008-09-26 Published:2020-10-13

摘要/Abstract

摘要： 目的:对比利奈唑胺与万古霉素及其他几种常用抗菌药物对临床分离阳性球菌的体外抗菌活性。方法:按照NCCLS(CLSI) 2007 纸片扩散法操作标准测定利奈唑胺与其他几种常用抗菌药物的体外抗菌活性。结果:本院分离的耐甲氧西林金黄色葡萄球菌(MRSA) 比例较高(79.1%), 利奈唑胺、万古霉素、替考拉宁的敏感率均达到100% 。耐甲氧西林凝固酶阴性葡萄球菌(MRCNS)的比例较MRSA 高(88.9%), 利奈唑胺与万古霉素、替考拉宁活性相当, 敏感率均为100% 。利奈唑胺对粪肠球菌的活性与万古霉素、替考拉宁相当, 对屎肠球菌的活性优于万古霉素和替考拉宁(100%, 80.4%, 78.1%), 对青霉素耐药的肺炎链球菌(PRSP) 也表现了优越的抗菌活性。结论:对于MRSA、MRCNS、PRSP、粪肠球菌, 利奈唑胺与万古霉素、替考拉宁的活性相当, 均为100% 的敏感率;对屎肠球菌的抗菌活性优于万古霉素和替考拉宁, 是治疗多药耐药阳性球菌感染的新型药物。

关键词: 利奈唑胺, 万古霉素, 阳性球菌, 多药耐药, 敏感性, 体外

Abstract: AIM: To compare the antibacterial activity of linezolid with vancomycin and other antibacterials against clinical gram-positive cocci isolates in vitro.METHODS: The antibacterial activity of linezolid and other antibacterials were determined according to the disk diffusion guidelines of NCCLS (CLSI) 2007 in vitro.RESULTS: The incidence of methicillin^- resistant Staphylococcus aureus (MRSA) isolated in our hospital was 79.1%, linezolid showed great susceptibility as well as vancomycin and teicoplanin.The incidence of methicillin-resistant coagulase negative Staphylococcus (MRCNS, 88.9%) was higher than that of MRSA, the antibacterial activity of linezolid was comparable with that of vancomycin and teicoplanin, and the sensitivity was 100%.The activity of linezolid against enterococcus faecalis is similar to that of vancomycin and teicoplanin, the activity of linezolid against enterococcus faecium is prior to that of vancomycin and teicoplanin (100%, 80.4%, 78.1%).Linezolid also showed great activity against penicillin resistant streptococcus pneumonia (PRSP).CONCLUSION: The antibacterial activity of linezolid was comparable with that of vancomycin and teicoplanin against MRSA, MRCNS, PRSP and enterococcus faecalis, and the sensitivity were all 100%.The antibacterial activity was better than those of the two drugs against enterococcus faecium in vitro.Linezolid could be a promising therapeutic option to treat infections caused by multi-resistant gram-positive cocci.

Key words: linezolid, vancomycin, gram-positivecocci, multidrugresistance, sensitivity, invitro

中图分类号:

R965.2

肖秀美, 刘振英, 张晓伟, 张捷. 利奈唑胺对临床分离阳性球菌的体外敏感性分析[J]. 中国临床药理学与治疗学, 2008, 13(9): 1048-1052.

XIAO Xiu-mei, LIU Zheng-ying, ZHANG Xiao-wei, ZHANG Jie. Sensitivity analyses of linezolid against clinical gram-positive cocci isolates in vitro[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(9): 1048-1052.

参考文献

[1] Rice LB.Antimicrobial resistance in gram-positive bacteria [J].Am J Infect Control, 2006, 34(5 Suppl 1):S11-9:discussion S64-73.
[2] Burleson BS, Ritchie DJ, Micek ST, et al. Enterococcus faecalis resistant to linezolid:case series and review of the literature [J].Pharmacotherapy, 2004, 24 (9):1225-1231.
[3] Moellering RC.Linezolid:the first oxazolidinone antimicrobial [J].Ann Intern Med, 2003, 138(2):135-142.
[4] French G.Linezolid [J].Int J Clin Pract, 2001, 55(1): 59-63.
[5] Schwalbe RS, Stapleton JT, Gilligan PH.Emergence of vancomycin resistance in coagulase-negative staphylococci [J].N Engl J Med, 1987, 316(15):927-931.
[6] Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility [J].J Antimicrob Chemother, 1997, 40(1):135-136.
[7] Credito K, Lin G, Appelbaum PC.Antistaphylococcal activity of DX-619 alone and in combination with vancomycin, teicoplanin, and linezolid assessed by time-kill synergy testing [J].Antimicrob Agents Chemother, 2007, 51 (4):1508-1511.
[8] Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections [J].Antimicrob Agents Chemother, 2005, 49 (6):2260-2266.
[9] Gee T, Ellis R, Marshall G, et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses [J].Antimicrob Agents Chemother, 2001, 45(6):1843-1846.
[10] Rybak MJ, Cappelletty DM, Moldovan T, et al. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomy cin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium [J].Antimicrob Agents Chemother, 1998, 42(3):721-724.
[11] Noskin GA, Siddiqui F, Stosor V, et al. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomy cin-resistant enterococci [J].Antimicrob Agents Chemother, 1999, 43(8):2059-2062.
[12] Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents [J].Antimicrob Agents Chemother, 1996, 40(4):839-845.
[13] Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus [J]. Lancet, 2001, 358(9277):207-208.
[14] Mutnick AH, Enne V, Jones RN.Linezolid resistance since 2001:SENTRY Antimicrobial Surveillance Program [J].Ann Pharmacother, 2003, 37(6):769-774.

[1]	张景惠, 卫浩亮, 王丽, 李京凯, 张宝来, 杨孝来. AMI-1通过下调PRMT5表达对胰腺癌细胞体外活性的影响[J]. 中国临床药理学与治疗学, 2023, 28(6): 601-608.
[2]	李珊, 柳熠鑫, 任菲菲, 李相晨, 张志清. 天然植物活性成分通过下调 P-糖蛋白逆转肿瘤多药耐药的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 331-340.
[3]	吴莉莉, 梁至, 黄思咏, 王妍. 肾功能亢进对感染性心内膜炎患者万古霉素药动学的影响及有效性与安全性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1139-1145.
[4]	谢梦蝶, 王衬衬, 李冰涛, 欧阳长生, 邱雨美, 李洪铭, 涂珺, 尚广彬, 汤喜兰. 基于体外细胞实验和网络药理学研究乳香挥发油抗心脏肥大的作用机制[J]. 中国临床药理学与治疗学, 2022, 27(3): 241-252.
[5]	胡琳璘, 徐思露, 厉伟兰, 何杰, 张锦璐, 邵华. 体外膜肺氧合技术对重症患者体内达托霉素药代药效学的影响[J]. 中国临床药理学与治疗学, 2022, 27(1): 39-46.
[6]	林良沫, 符祥俊, 钟莉莉, 王和芳, 吴琼诗, 肖坚. 中性粒细胞缺乏患者万古霉素群体药代动力学模型的建立[J]. 中国临床药理学与治疗学, 2021, 26(9): 1014-1022.
[7]	焦志刚, 凡如, 许碧云, 陈思臻, 臧一腾, 王诗远, 陈炳为. 临床纵向数据缺失的多重填补及其敏感性分析[J]. 中国临床药理学与治疗学, 2021, 26(9): 1037-1041.
[8]	刘馨, 冷玉芳, 张学红, 张莉莉, 张梦婕, 瞿珊珊, 谢建琴, 王一青. 纳布啡在超声引导下经阴道穿刺取卵术中的应用及对胚胎质量和妊娠结局的影响[J]. 中国临床药理学与治疗学, 2021, 26(9): 1042-1047.
[9]	孟强, 刘克辛. 转运体介导药物相互作用的研究现状及展望[J]. 中国临床药理学与治疗学, 2021, 26(8): 876-888.
[10]	周晗, 刘晓东. 生理药代动力学模型在创新药物评价中应用及其若干问题的思考[J]. 中国临床药理学与治疗学, 2021, 26(8): 889-913.
[11]	刘文静, 武之涛, 潘国宇. 肝毒性风险的体外早期发现和预测[J]. 中国临床药理学与治疗学, 2021, 26(8): 923-930.
[12]	符祥俊, 黄莉, 郭丽, 林良沫. 万古霉素AUC/MIC在多重耐药革兰阳性菌致重症感染中的应用分析[J]. 中国临床药理学与治疗学, 2021, 26(7): 775-781.
[13]	鲁琼, 朱海宏, 戚听听, 李国华, 滕欣琪, 屈强, 屈健. OCTN2基因多态性影响结直肠癌奥沙利铂化疗敏感性[J]. 中国临床药理学与治疗学, 2021, 26(4): 401-407.
[14]	寇晨, 李兆娜, 张亚南, 高正平, 张拓慧. 应用蒙特卡洛模拟评价新生儿革兰阳性球菌晚发型败血症的药敏变迁[J]. 中国临床药理学与治疗学, 2021, 26(12): 1400-1406.
[15]	郭仙忠, 林荣芳, 林玮玮. 基于群体药动学模型的万古霉素个体化给药软件研制及应用[J]. 中国临床药理学与治疗学, 2021, 26(1): 30-39.